{"id":37059,"date":"2025-07-10T13:52:35","date_gmt":"2025-07-10T05:52:35","guid":{"rendered":"https:\/\/flcube.com\/?p=37059"},"modified":"2025-07-10T13:52:36","modified_gmt":"2025-07-10T05:52:36","slug":"msd-to-acquire-verona-pharma-for-10-billion-expanding-respiratory-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37059","title":{"rendered":"MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio"},"content":{"rendered":"\n<p>In a landmark deal poised to reshape the respiratory disease treatment landscap US pharmaceutical giant Merck, Sharp &amp; Dohme (<strong>MSD, <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a><\/strong>) has agreed to acquire <strong>Verona Pharma plc (<a href=\"https:\/\/www.google.com\/finance\/quote\/VRNA:NASDAQ\">NASDAQ: VRNA<\/a>)<\/strong>, a UK-based biopharmaceutical company, for <strong>USD 10 billion<\/strong>. The acquisition price is set at <strong>USD 107 per American Depositary Share (ADS)<\/strong>, marking one of the largest deals in recent biopharma history.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-strategic-acquisition-and-portfolio-expansion\"><strong>Strategic Acquisition and Portfolio Expansion<\/strong><\/h4>\n\n\n\n<p>The acquisition underscores Merck&#8217;s strategic intent to bolster its cardiopulmonary pipeline by integrating Verona Pharma&#8217;s innovative assets. Central to this deal is <strong>Ohtuvayre (ensifentrine)<\/strong>, a groundbreaking treatment for chronic obstructive pulmonary disease (COPD). Ohtuvayre represents a first-in-class dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), offering a novel mechanism of action that combines bronchodilatory and anti-inflammatory effects.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-ohtuvayre-s-clinical-and-market-significance\"><strong>Ohtuvayre\u2019s Clinical and Market Significance<\/strong><\/h4>\n\n\n\n<p>Approved by the U.S. FDA in June 2024 for the maintenance treatment of COPD in adult patients, Ohtuvayre is the first novel inhaled therapy for COPD in over two decades. Its unique dual-action approach addresses a significant unmet need in respiratory care, providing both symptom relief and disease modification.<\/p>\n\n\n\n<p>Additionally, Ohtuvayre is currently under evaluation in clinical trials for non-cystic fibrosis bronchiectasis, further expanding its potential to address underserved patient populations.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-licensing-agreement-with-nuance-pharma\"><strong>Licensing Agreement with Nuance Pharma<\/strong><\/h4>\n\n\n\n<p>Prior to the acquisition, Verona Pharma had established a strategic partnership with China-based Nuance Pharma in 2021. Under this agreement, Nuance Pharma secured Greater China rights to Ohtuvayre, involving:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>USD 25 million<\/strong> upfront payment.<\/li>\n\n\n\n<li><strong>USD 15 million<\/strong> equity investment in Verona Pharma.<\/li>\n\n\n\n<li>Potential <strong>USD 179 million<\/strong> in milestone payments.<\/li>\n<\/ul>\n\n\n\n<p>This partnership highlights the global interest in Ohtuvayre and its potential to become a cornerstone therapy in respiratory medicine.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-merck-s-vision-for-respiratory-innovation\"><strong>Merck\u2019s Vision for Respiratory Innovation<\/strong><\/h4>\n\n\n\n<p>The acquisition aligns with Merck&#8217;s commitment to advancing innovative treatments for cardiopulmonary diseases. By adding Ohtuvayre to its portfolio, Merck strengthens its position as a leader in respiratory care, offering patients and healthcare providers a differentiated therapeutic option that addresses both the symptoms and underlying mechanisms of COPD.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-conclusion\"><strong>Conclusion<\/strong><\/h4>\n\n\n\n<p>This USD 10 billion acquisition is a testament to the strategic value of innovative therapies in addressing significant unmet medical needs. As Merck &amp; Co. integrates Verona Pharma\u2019s assets, the combined entity is poised to make a meaningful impact on the lives of millions of patients worldwide suffering from respiratory diseases.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a landmark deal poised to reshape the respiratory disease treatment landscap US pharmaceutical giant&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37060,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2675,176,3638,903,3637],"class_list":["post-37059","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-merck-sharp-dohme","tag-msd","tag-nasdaq-vrna","tag-nyse-mrk","tag-verona-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"In a landmark deal poised to reshape the respiratory disease treatment landscap US pharmaceutical giant Merck, Sharp &amp; Dohme (MSD, NYSE: MRK) has agreed to acquire Verona Pharma plc (NASDAQ: VRNA), a UK-based biopharmaceutical company, for USD 10 billion. The acquisition price is set at USD 107 per American Depositary Share (ADS), marking one of the largest deals in recent biopharma history.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37059\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio\" \/>\n<meta property=\"og:description\" content=\"In a landmark deal poised to reshape the respiratory disease treatment landscap US pharmaceutical giant Merck, Sharp &amp; Dohme (MSD, NYSE: MRK) has agreed to acquire Verona Pharma plc (NASDAQ: VRNA), a UK-based biopharmaceutical company, for USD 10 billion. The acquisition price is set at USD 107 per American Depositary Share (ADS), marking one of the largest deals in recent biopharma history.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37059\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-10T05:52:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-10T05:52:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37059#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37059\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio\",\"datePublished\":\"2025-07-10T05:52:35+00:00\",\"dateModified\":\"2025-07-10T05:52:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37059\"},\"wordCount\":391,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37059#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1001.webp\",\"keywords\":[\"Merck Sharp &amp; Dohme\",\"MSD\",\"NASDAQ: VRNA\",\"NYSE: MRK\",\"Verona Pharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37059#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37059\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37059\",\"name\":\"MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37059#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37059#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1001.webp\",\"datePublished\":\"2025-07-10T05:52:35+00:00\",\"dateModified\":\"2025-07-10T05:52:36+00:00\",\"description\":\"In a landmark deal poised to reshape the respiratory disease treatment landscap US pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has agreed to acquire Verona Pharma plc (NASDAQ: VRNA), a UK-based biopharmaceutical company, for USD 10 billion. The acquisition price is set at USD 107 per American Depositary Share (ADS), marking one of the largest deals in recent biopharma history.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37059#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37059\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37059#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1001.webp\",\"width\":1080,\"height\":608,\"caption\":\"MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37059#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"In a landmark deal poised to reshape the respiratory disease treatment landscap US pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has agreed to acquire Verona Pharma plc (NASDAQ: VRNA), a UK-based biopharmaceutical company, for USD 10 billion. The acquisition price is set at USD 107 per American Depositary Share (ADS), marking one of the largest deals in recent biopharma history.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37059","og_locale":"en_US","og_type":"article","og_title":"MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio","og_description":"In a landmark deal poised to reshape the respiratory disease treatment landscap US pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has agreed to acquire Verona Pharma plc (NASDAQ: VRNA), a UK-based biopharmaceutical company, for USD 10 billion. The acquisition price is set at USD 107 per American Depositary Share (ADS), marking one of the largest deals in recent biopharma history.","og_url":"https:\/\/flcube.com\/?p=37059","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-10T05:52:35+00:00","article_modified_time":"2025-07-10T05:52:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37059#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37059"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio","datePublished":"2025-07-10T05:52:35+00:00","dateModified":"2025-07-10T05:52:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37059"},"wordCount":391,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37059#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1001.webp","keywords":["Merck Sharp &amp; Dohme","MSD","NASDAQ: VRNA","NYSE: MRK","Verona Pharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37059#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37059","url":"https:\/\/flcube.com\/?p=37059","name":"MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37059#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37059#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1001.webp","datePublished":"2025-07-10T05:52:35+00:00","dateModified":"2025-07-10T05:52:36+00:00","description":"In a landmark deal poised to reshape the respiratory disease treatment landscap US pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has agreed to acquire Verona Pharma plc (NASDAQ: VRNA), a UK-based biopharmaceutical company, for USD 10 billion. The acquisition price is set at USD 107 per American Depositary Share (ADS), marking one of the largest deals in recent biopharma history.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37059#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37059"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37059#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1001.webp","width":1080,"height":608,"caption":"MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37059#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37059"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37059\/revisions"}],"predecessor-version":[{"id":37061,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37059\/revisions\/37061"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37060"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}